Eli Lilly and Company $LLY Shares Sold by K.J. Harrison & Partners Inc

K.J. Harrison & Partners Inc cut its stake in shares of Eli Lilly and Company (NYSE:LLY) by 13.9% during the 2nd quarter, according to its most recent filing with the SEC. The institutional investor owned 5,582 shares of the company’s stock after selling 898 shares during the period. K.J. Harrison & Partners Inc’s holdings in Eli Lilly and Company were worth $4,351,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently bought and sold shares of LLY. Machina Capital S.A.S. increased its holdings in Eli Lilly and Company by 35.4% during the 2nd quarter. Machina Capital S.A.S. now owns 2,443 shares of the company’s stock worth $1,904,000 after purchasing an additional 639 shares during the last quarter. Westside Investment Management Inc. increased its holdings in Eli Lilly and Company by 7.7% during the 2nd quarter. Westside Investment Management Inc. now owns 2,120 shares of the company’s stock worth $1,652,000 after purchasing an additional 152 shares during the last quarter. Snider Financial Group increased its holdings in Eli Lilly and Company by 3.8% during the 2nd quarter. Snider Financial Group now owns 12,266 shares of the company’s stock worth $9,562,000 after purchasing an additional 450 shares during the last quarter. Benchmark Financial Wealth Advisors LLC increased its holdings in Eli Lilly and Company by 3.1% during the 2nd quarter. Benchmark Financial Wealth Advisors LLC now owns 912 shares of the company’s stock worth $711,000 after purchasing an additional 27 shares during the last quarter. Finally, W.G. Shaheen & Associates DBA Whitney & Co increased its holdings in Eli Lilly and Company by 5.1% during the 2nd quarter. W.G. Shaheen & Associates DBA Whitney & Co now owns 9,166 shares of the company’s stock worth $7,145,000 after purchasing an additional 448 shares during the last quarter. 82.53% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

LLY has been the topic of several analyst reports. Daiwa America downgraded Eli Lilly and Company from a “strong-buy” rating to a “hold” rating in a report on Sunday, August 17th. Hsbc Global Res upgraded Eli Lilly and Company from a “moderate sell” rating to a “hold” rating in a report on Wednesday, August 27th. Morgan Stanley dropped their price objective on Eli Lilly and Company from $1,028.00 to $1,023.00 and set an “overweight” rating on the stock in a report on Friday, October 3rd. BMO Capital Markets lifted their price objective on Eli Lilly and Company from $840.00 to $930.00 and gave the stock an “outperform” rating in a report on Monday, October 20th. Finally, HSBC lifted their price objective on Eli Lilly and Company from $700.00 to $800.00 in a report on Wednesday, October 1st. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and nine have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $940.00.

Eli Lilly and Company Price Performance

Shares of NYSE LLY opened at $862.96 on Monday. Eli Lilly and Company has a twelve month low of $623.78 and a twelve month high of $935.63. The company has a current ratio of 1.28, a quick ratio of 1.00 and a debt-to-equity ratio of 1.86. The company has a market capitalization of $816.75 billion, a price-to-earnings ratio of 56.40, a price-to-earnings-growth ratio of 1.21 and a beta of 0.47. The business has a 50 day simple moving average of $780.74 and a 200-day simple moving average of $771.97.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts’ consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion during the quarter, compared to the consensus estimate of $16.09 billion. Eli Lilly and Company had a return on equity of 92.72% and a net margin of 25.91%.The firm’s revenue was up 53.9% on a year-over-year basis. During the same period in the prior year, the business earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. As a group, equities research analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 10th. Investors of record on Friday, November 14th will be paid a dividend of $1.50 per share. This represents a $6.00 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date is Friday, November 14th. Eli Lilly and Company’s dividend payout ratio is presently 29.35%.

Insider Activity

In related news, EVP Daniel Skovronsky acquired 1,000 shares of the stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $634.40 per share, for a total transaction of $634,400.00. Following the purchase, the executive vice president directly owned 137,660 shares in the company, valued at $87,331,504. This represents a 0.73% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this link. Also, Director Gabrielle Sulzberger acquired 117 shares of the stock in a transaction that occurred on Tuesday, August 12th. The shares were bought at an average price of $641.18 per share, with a total value of $75,018.06. Following the completion of the purchase, the director owned 2,703 shares in the company, valued at $1,733,109.54. The trade was a 4.52% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders purchased 4,514 shares of company stock worth $2,894,841 over the last 90 days. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.